“Que se passera-t-il si les annonceurs se rendent compte que la moitié de leurs bannières ne seront jamais vues ? Pour les éditeurs, le débat n’est pas là. Pour les annonceurs, il ne faut pas en [...]”
Toward the end of 2014 the Blue Latitude team gathered together for breakfast in the boardroom to discuss how pharma marketing will change in the year ahead and what trends will be big in pharma marketing during 2015.
Sales Reps and the New Commercial Organization PharmExec.com Structural transformations in the life sciences industry have put the traditional sales role under increasing scrutiny, with the most prominent change being a drastic reduction in field...
Biogen Idec has partnered with Google X, Google’s business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), according to a report from Bloomberg.
Google and Biogen will use sensors, software, and data analysis tools to collect and analyze data from people who have MS. The companies aim to explore why MS progresses differently in each patient.
Bloomberg pointed out that Biogen has used digital tools for its disease research in the past. Last month, Biogen announced that it was using Fitbit activity trackers to gather data from people who have MS. It gave 250 Fitbit bands to participants to track their level of activity and sleep patterns. Last summer, the pharma company worked with Cleveland Clinic to develop an iPad app to assess MS progression.